Evidence map›Paper›PMID 39240934›Full record

ArticlePloS one2024

Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK.

Mark Postans, Nicole Pacchiarini, Jiao Song, Simon Cottrell, Catie Williams, Andrew Beazer, Catherine Moore, Thomas R Connor, Christopher Williams

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mark PostansCommunicable Disease Surveillance Centre (CDSC), Public Health Wales, Cardiff, Wales, United Kingdom.ORCID 0000-0002-8803-7259
Nicole PacchiariniCommunicable Disease Surveillance Centre (CDSC), Public Health Wales, Cardiff, Wales, United Kingdom.
Jiao SongCommunicable Disease Surveillance Centre (CDSC), Public Health Wales, Cardiff, Wales, United Kingdom.
Simon CottrellCommunicable Disease Surveillance Centre (CDSC), Public Health Wales, Cardiff, Wales, United Kingdom.
Catie WilliamsPathogen Genomics Unit, Public Health Wales, Cardiff, Wales, United Kingdom.ORCID 0000-0003-3654-3923
Andrew BeazerPathogen Genomics Unit, Public Health Wales, Cardiff, Wales, United Kingdom.ORCID 0000-0002-9045-3120
Catherine MooreWales Specialist Virology Centre, Microbiology, Public Health Wales, Cardiff, Wales, United Kingdom.
Thomas R ConnorPathogen Genomics Unit, Public Health Wales, Cardiff, Wales, United Kingdom.
Christopher WilliamsCommunicable Disease Surveillance Centre (CDSC), Public Health Wales, Cardiff, Wales, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies suggest an increased risk of reinfection with the SARS-CoV-2 Omicron variant compared with previous variants, potentially due to an increased ability to escape immunity specific to older variants, high antigenic divergence of Omicron from earlier virus variants as well as its altered cell entry pathway. The present study sought to investigate epidemiological evidence for differential SARS-CoV-2 reinfection intervals and incidence rates for the Delta versus Omicron variants within Wales. Reinfections in Wales up to February 2022 were defined using genotyping and whole genome sequencing. The median inter-infection intervals for Delta and Omicron were 226 and 192 days, respectively. An incidence rate ratio of 2.17 for reinfection with Omicron compared to Delta was estimated using a conditional Poisson model, which accounted for several factors including sample collection date, age group, area of residence, vaccination and travel status. These findings are consistent with an increased risk of reinfection with the Omicron variant, and highlight the value of monitoring emerging variants that have the potential for causing further waves of cases.

Indexed as

COVID-19ReinfectionSARS-CoV-2AdolescentAdultAgedChildChild, PreschoolFemaleHumansIncidenceInfantMaleMiddle AgedWalesYoung Adult

Identifiers

PMID39240934
PMCPMC11379141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.